↑ 疾患リストへ ← 戻る

 222. 一次性ネフローゼ症候群 [臨床試験数:152,薬物数:167(DrugBank:61),標的遺伝子数:48,標的パスウェイ数:44] 

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03970577December 1, 20194 November 2019RItuximab From the FIRst Episode of Idiopathic Nephrotic SyndromeRituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled TrialMinimal Change Nephrotic Syndrome (MCNS)Drug: Rituximab;Drug: PrednisoneAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/AAll148Phase 2
2NCT04154787November 29, 201911 November 2019Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous NephropathyA Randomized, Treatment Open-label, Dose-blinded Parallel Group, Three Arm, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous NephropathyGlomerulonephritis, MembranousDrug: LNP023;Drug: RituximabNovartis PharmaceuticalsNot recruiting18 YearsN/AAll72Phase 2
3NCT02399462November 20197 October 2019Acthar for Treatment of Post-transplant FSGSActhar for Treatment of Post-transplant FSGSFSGS;Renal Transplantation;Kidney TransplantationDrug: ActharUniversity of North Carolina, Chapel HillMallinckrodtNot recruiting18 YearsN/AAll20Phase 4United States
4NCT03949855November 201914 October 2019Belimumab With Rituximab for Primary Membranous NephropathyEfficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)Membranous Nephropathy;MNDrug: Rituximab;Drug: Placebo for Belimumab;Drug: BelimumabNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN);GlaxoSmithKlineNot recruiting18 Years75 YearsAll124Phase 2United States;Canada
5NCT04145440October 15, 20194 November 2019Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)Glomerulonephritis, Membranous;antiPLA2R PositiveDrug: MOR202MorphoSys AGMetronomia;Q2 Solutions;IQVIA LtdRecruiting18 Years80 YearsAll30Phase 1/Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04009668October 2, 201914 October 2019Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseasePrecision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseFSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change DiseaseDrug: adalimumabUniversity of MichiganNew York UniversityRecruiting6 Years70 YearsAll8Phase 2United States
7JPRN-UMIN0000382422019/10/015 November 2019The effect of Evolocumab on primary nephrotic syndromeThe effect of Evolocumab on primary nephrotic syndrome - The effect of Evolocumab on primary nephrotic syndromePrimary nephrotic syndromeEvolocumabDepartment of Nephrology, Nippon Medical SchoolRecruiting16years-oldNot applicableMale and Female10Not selectedJapan
8NCT03804359September 201926 August 2019Personalized Medicine for Membranous NephropathyPersonalized Medicine for Membranous NephropathyIdiopathic Membranous NephropathyDrug: RituximabCentre Hospitalier Universitaire de NiceNot recruiting18 YearsN/AAll64Phase 2France
9NCT03763643July 1, 201911 November 2019PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantPRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantFocal Segmental GlomerulosclerosisDrug: Rituximab;Drug: Placebo;Procedure: PlasmapheresisUniversity of MinnesotaUnited States Department of DefenseRecruiting1 Year40 YearsAll160Phase 1/Phase 2United States
10ChiCTR19000229432019-05-035 May 2019Population Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic SyndromePopulation Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic SyndromeNephrotic SyndromeCase Series:Tacrolimus;Children's Hospital, Zhejiang University School of MedicineRecruitingBothCase Series:100;Phase 4China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2018-003437-15-FR03/04/201930 April 2019Rituximab from the FIRst Episode of Idiopathic Nephrotic SyndromeRituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome - RIFIREINSMinimal Change Nephrotic Syndrome (MCNS)
MedDRA version: 20.0 Level: LLT Classification code 10029168 Term: Nephrotic syndrome with lesion of minimal change glomerulonephritis System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: MabThera
Product Name: MabThera
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
ASSISTANCE PUBLIQUE - HOPITAUX DE PARISAuthorised Female: yes
Male: yes
148Phase 2France
12ChiCTR19000217572019-03-0111 March 2019A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathyThe efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trialIdiopathic Membranous NephropathyGroup 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d);Nephrology Division, First Hospital Affiliated to Army Medical UniversityRecruiting1860BothGroup 1:55;Group 2:55;Group 3:55;Group 4:55;Phase 4China
13ChiCTR18000198332019-01-014 December 2018Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormoneDynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormoneIdiopathic Membranous NephropathyPLA2R???:Cyclophosphamide combined with hormone therapy ;PLA2R positive Group:Cyclophosphamide combined with hormone therapy;Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical UniversityNot Recruiting1885MalePLA2R???:30;PLA2R positive Group:30;Pilot studyChina
14ChiCTR18000202412019-01-0114 January 2019Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin DDisease diagnosis and treatment technology and standardized research and development and application demonstrationIdiopathic membranous nephropathyVitamin D group:Active Vitamin D 0.5ug/day;Valsartan group:Valsartan capsule 160mg/day;Combined treatment group:Active vitamin D 0.5ug / day + valsartan capsule 160mg / day;The People's Hospital of Guangxi Zhuang Autonomous RegionRecruiting14100BothVitamin D group:40;Valsartan group:40;Combined treatment group:40;OtherChina
15NCT03864250November 26, 201815 July 2019Tacrolimus Monotherapy for Idiopathic Membranous NephropathyTacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical TrialTacrolimus;Idiopathic Membranous Nephropathy;Clinical TrialDrug: Tacrolimus;Drug: PrednisoneXinhua Hospital, Shanghai Jiao Tong University School of MedicineRecruiting18 Years80 YearsAll124N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2016-005141-23-PL20/11/20184 December 2018Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS)A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)Focal segmental glomerulosclerosis (FSGS)
MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
Product Name: over-encapsulated 75 mg Irbesartan Tablets
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Retrophin, Inc.AuthorisedFemale: yes
Male: yes
300Phase 3United States;Taiwan;Spain;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;South Africa;Germany;Korea, Republic of
17NCT03448692October 15, 20189 September 2019A Study To Evaluate PF-06730512 In Adults With Primary Focal Segmental GlomerulosclerosisA PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)Focal Segmental Glomerulosclerosis (FSGS)Drug: PF-06730512PfizerRecruiting18 YearsN/AAll44Phase 2United States;Canada
18NCT03703908October 1, 201824 June 2019A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic SyndromeAn Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic SyndromeFocal Segmental GlomerulosclerosisDrug: CCX140-BChemoCentryxRecruiting18 YearsN/AAll13Phase 2United States
19EUCTR2016-005141-23-ES28/09/201810 October 2018Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS)A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)Focal segmental glomerulosclerosis (FSGS)
MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
Product Name: over-encapsulated 75 mg Irbesartan Tablets
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Retrophin, Inc.AuthorisedFemale: yes
Male: yes
300Phase 3United States;Taiwan;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;South Africa;Germany;Korea, Republic of
20NCT03649152September 17, 201810 December 2018Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving IrbesartanA Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving IrbesartanFocal Segmental GlomerulosclerosisDrug: Propagermanium;Drug: PlaceboDimerix Bioscience Pty LtdIQVIARecruiting18 Years80 YearsAll10Phase 2Australia
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2016-005141-23-CZ05/09/20187 January 2019Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS)A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)Focal segmental glomerulosclerosis (FSGS)
MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Irbesartan tablets
Product Name: over-encapsulated Irbesartan Tablets
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Retrophin, Inc.AuthorisedFemale: yes
Male: yes
300Phase 3United States;Taiwan;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;Germany;Korea, Republic of
22NCT03298698August 22, 20183 September 2018Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeEfficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose PrednisoneIdiopathic Nephrotic Syndrome;Minimal Change Disease;Focal Segmental GlomerulosclerosisDrug: Rituximab;Drug: PrednisoneRadboud UniversityRecruiting18 YearsN/AAll40Phase 3Netherlands
23NCT03549663July 4, 201815 April 2019Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)Idiopathic Membranous NephropathyDrug: Tacrolimus;Drug: PrednisoneXinhua Hospital, Shanghai Jiao Tong University School of MedicineRecruiting18 Years80 YearsAll108N/AChina
24ChiCTR18000161402018-07-0121 May 2018Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamide in the treatment of adult primary membranous nephropathy: a multicenter, controlled, open studyA randomized controlled trial for the treatment of primary membranous nephropathyprimary membranous nephropathyTacrolimus group:Tacrolimus 0.05-0.1mg/kg/d;Cyclophosphamide group:CTX 750mg/m2 ivgtt q2w for 8 weeks, then q4w for 4 weeks;Sichuan Provincial People's HospitalNot Recruiting1865BothTacrolimus group:45;Cyclophosphamide group:45;Post-marketChina
25NCT03170323July 1, 20181 April 2019Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous NephropathyA Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous NephropathyIdiopathic Membranous NephropathyDrug: Cyclosporins;Drug: Mycophenolate MofetilGuangdong General HospitalRecruiting18 YearsN/AAll128Phase 4China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT03598036June 21, 201826 August 2019Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental GlomerulosclerosisAn Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: VoclosporinAurinia Pharmaceuticals Inc.Recruiting18 Years75 YearsAll20Phase 2United States;Dominican Republic
27NCT03459443June 20, 201830 September 2019A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471C3 Glomerulonephritis;C3 Glomerulopathy;Immune Complex Membranoproliferative Glomerulonephritis;IC-MPGN;Dense Deposit DiseaseDrug: ACH-0144471Achillion PharmaceuticalsNot recruiting17 Years65 YearsAll22Phase 2United States;Australia;Belgium;Italy;Netherlands
28EUCTR2017-003021-15-PL19/06/201815 October 2018A controlled study to evaluate the safety and efficacy of the study drug, CCX140-B, in subjects with Focal Segmental Glomerulosclerosis (a type of glomerular disease)A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: CCX140-B
Pharmaceutical Form: Tablet
INN or Proposed INN: INN not available yet
Current Sponsor code: CCX140-B
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
ChemoCentryx, Inc.AuthorisedFemale: yes
Male: yes
40Phase 2France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom
29NCT03536754May 1, 20182 September 2019A Study of CCX140-B in Subjects With FSGSA Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)FSGS;Focal Segmental Glomerulosclerosis;GlomerulosclerosisOther: Placebo;Drug: CCX140-BChemoCentryxMedpace, Inc.Not recruiting18 Years75 YearsAll46Phase 2United States;Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom
30NCT03422510April 15, 201826 August 2019FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)Primary Focal Segmental GlomerulosclerosisDrug: CXA-10Complexa, Inc.Kidney Research Network, formerly NephCure Accelerating Cures Institute;Medpace, Inc.;MicroConstants;Arkana Labs;NephCure Kidney InternationalRecruiting18 YearsN/AAll30Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT03493685March 29, 201826 August 2019Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGSFocal Segmental GlomerulosclerosisDrug: sparsentan;Drug: irbesartanRetrophin, Inc.Recruiting8 Years75 YearsAll300Phase 3United States;Australia;Canada;Czechia;Denmark;Estonia;France;Hungary;Italy;Korea, Republic of;Poland;Spain;Taiwan;United Kingdom
32NCT03466801March 20, 201811 June 2018The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I.Idiopathic Membranous NephropathyDrug: Prednisone;Drug: MP and CTXWenhu LiuNot recruiting18 Years80 YearsAll166N/A
33NCT03025828March 19, 20181 April 2019Adrenocorticotropic Hormone in Membranous NephropathyChanges in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous NephropathyMembranous NephropathyDrug: ACTHarIcahn School of Medicine at Mount SinaiRecruiting18 Years70 YearsAll25Phase 4United States
34ChiCTR18000147192018-02-015 February 2018A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosisA retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosisidiopathic focal segmental glomerulosclerosistacrolimus group:nothing;prednisone group:nothing;the First Affiliated Hospital of Third Military Medical UniversityRecruitingBothtacrolimus group:24;prednisone group:17;Retrospective studyChina
35NCT03453619January 22, 201828 January 2019Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesA Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit DiseaseDrug: APL-2Apellis Pharmaceuticals, Inc.Recruiting18 YearsN/AAll48Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2017-001821-42-BE15/01/201828 February 2019A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 GlomerulopathyC3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN).
MedDRA version: 20.0 Level: PT Classification code 10077827 Term: C3 glomerulopathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Avacopan
Product Code: CCX168
Pharmaceutical Form: Capsule
INN or Proposed INN: AVACOPAN
CAS Number: 1346623-17-3
Current Sponsor code: CCX168
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
ChemoCentryx, Inc.Authorised Female: yes
Male: yes
88Phase 2France;United States;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom
37NCT03366337December 26, 201724 June 2019A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXA Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney DiseasesIgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic KidneyDrug: Bardoxolone methyl capsulesReata Pharmaceuticals, Inc.Not recruiting18 Years65 YearsAll103Phase 2United States
38EUCTR2017-003366-27-NL21/12/20178 January 2018Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndromeEfficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone. - Rituximab in SRNSIdiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]Product Name: Rituximab
Pharmaceutical Form: Concentrate for solution for injection/infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: equal
Concentration number: 375-
Product Name: Prednisolone
Pharmaceutical Form: Tablet
INN or Proposed INN: Prednisolone
Other descriptive name: PREDNISOLONE ACETATE
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 1-
Radboud University Nijmegen Medical CenterAuthorisedFemale: yes
Male: yes
40Phase 3Netherlands
39NCT03285711October 6, 201728 October 2019Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)Lupus Membranous NephropathyDrug: Filgotinib;Drug: Lanraplenib;Drug: Filgotinib placebo;Drug: Lanreplenib placeboGilead SciencesNot recruiting18 Years75 YearsAll9Phase 2United States
40ChiCTR-INR-170120702017-09-1924 July 2017Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathyYongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathyMembranous nephropathyTest group :Yongquan Shenque paste of Chinese medicine with mild moxibustion;control group:Valsartan Tablets;Shijiazhuang Nephropathy HospitalNot Recruiting1875BothTest group :75;control group:75;New Treatment Measure Clinical StudyChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT03095118September 7, 201728 October 2019Daratumumab in Treatment of PGNMID and C3 GNSingle-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal GammopathyMembranoproliferative GlomerulonephritisDrug: DaratumumabFernando FervenzaRecruiting18 YearsN/AAll10Phase 2United States
42NCT03124368August 9, 201711 November 2019A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGNA Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulonephritis;Dense Deposit Disease;Membranoproliferative Glomerulonephritis, Type II;C3 Glomerulopathy;Immune Complex Mediated Membranoproliferative GlomerulonephritisDrug: ACH-0144471Achillion PharmaceuticalsNot recruiting16 Years65 YearsAll6Phase 2Australia;Belgium;Netherlands
43ChiCTR-INR-170122122017-07-2821 August 2017Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trialUse of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trialidiopathic membranous nephropathy1:Cyclosporine;2:cyclosporine combined with sirolimus;Renal Division, Peking University First HospitalRecruiting1870Both1:35;2:35;New Treatment Measure Clinical StudyChina
44ChiCTR-IPR-170117022017-07-016 November 2017Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroidCompare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroidmembranous nephropathymizoribine group:treated with mizoribine and steroid;cyclophosphamide group:treated with cyclophosphamide and steroid;Tianjin First Central HospitalNot Recruiting1865Bothmizoribine group:50;cyclophosphamide group:50;Post-marketChina
45NCT03180723July 1, 201716 December 2017Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisEffect of Rituximab in Treatment of Primary Membranoproliferative GlomerulonephritisMembranoproliferative GlomerulonephritisDrug: Rituximab;Drug: CyclosporinAssiut UniversityNot recruiting18 YearsN/AAll30Phase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT02921789May 22, 201726 August 2019Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsA Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsKidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS)Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: PrednisoneAstellas Pharma Global Development, Inc.Kyowa Kirin Co., Ltd.Recruiting18 YearsN/AAll60Phase 2United States;Canada
47NCT02896270October 201616 December 2017Valproic Acid for Idiopathic Nephrotic SyndromeA Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic SyndromeIdiopathic Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change DiseaseDrug: Valproic AcidUniversitair Ziekenhuis BrusselRecruiting18 YearsN/AAll15Phase 2/Phase 3Belgium
48NCT02683889August 201614 November 2016Use of Acthar in Patients With FSGS That Will be Undergoing Renal TransplantationThe Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal TransplantFSGSDrug: ActharGeorgetown UniversityRecruiting18 Years80 YearsBoth20Phase 3United States
49NCT02966717August 201628 November 2016Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)Renal Insufficiency, Chronic;Nephrotic SyndromeDrug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cellsZhujiang HospitalNot recruiting18 Years65 YearsBoth116Phase 2China
50NCT02633046May 16, 201630 September 2019Acthar for Treatment-Resistant or Treatment-Intolerant ProteinuriaTreatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)Idiopathic Focal Segmental GlomerulosclerosisDrug: Acthar 80 U 3x/week;Other: Placebo;Drug: Acthar 80 U 2x/weekMallinckrodtNot recruiting18 YearsN/AAll64Phase 4United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51JPRN-UMIN0000221502016/04/302 April 2019The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome.primary nephrotic syndromerituximabTokyo Metropolitan Geriatric HospitalRecruiting18years-oldNot applicableMale and Female50Not applicableJapan
52ChiCTR-IPR-160083442016-04-1918 April 2017A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid plus tacrolimus in idiopathic membranous nephropathyA study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid Plus tacrolimus in idiopathic membranous nephropathyidiopathic membranous nephropathyA:cyclophosphamide ;B:tacrolimus;Baoji Central HospitalRecruitingBothA:30;B:30;Post-marketChina
53NCT02592798March 1, 201626 August 2019Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change DiseaseOther: D5W;Other: Normal Saline;Drug: AbataceptBristol-Myers SquibbNot recruiting6 YearsN/AAll90Phase 2United States
54NCT02682407February 201622 January 2018Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit DiseaseIgAN;Lupus Nephritis;MN;C3GBiological: OMS721;Other: Vehicle (D5W)Omeros CorporationRecruiting18 YearsN/AAll44Phase 2United States
55NCT02610595December 20157 December 2015Study on the Therapeutic Effect of TCM Treatment for MDR MNA Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation)Idiopathic Membranous NephropathyDrug: Jianpixiaozhong particles and Wuse DietotherapyShanghai University of Traditional Chinese MedicineFudan University;Ruijin Hospital;Shanghai 6th People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Changhai Hospital;Shanghai Putuo District Center Hospital;ShuGuang Hospital;Shanghai Yueyang Integrated Medicine Hospital;Shanghai Changzheng Hospital;Shanghai Minhang Central Hospital;Zhujiang Hospital;Guangxi Traditional Chinese Medical University;Huashan Hospital;The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;Xinqiao Hospital of Chongqing;Guang'anmen Hospital of China Academy of Chinese Medical Sciences;Nanjing University of Traditional Chinese Medicine;Tongji Hospital;Chinese Academy of Sciences;RenJi HospitalNot recruiting18 Years75 YearsBoth220N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT02585804September 201522 January 2018Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial EffectsTreating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE StudyFocal Segmental GlomerulosclerosisDrug: DapagliflozinUniversity Health Network, TorontoAstraZeneca;University of Toronto;Toronto General HospitalNot recruiting18 YearsN/AAll10Phase 4Canada
57NCT02693366June 201516 December 2017Stem Cell Therapy for Patients With Focal Segmental GlomerulosclerosisSafety Study of the Endovascular Infusion of Bone Marrow Derived Mononuclear Cells in Patients With Focal Segmental GlomerulosclerosisGlomerulosclerosis, Focal Segmental;Renal Insufficiency, ChronicBiological: Autologous Cell TransplantationUniversidade Federal do Rio de JaneiroMinistry of Science and Technology, Brazil;Ministry of Health, Brazil;National Research Council, Brazil;Rio de Janeiro State Research Supporting Foundation (FAPERJ)Not recruiting18 Years60 YearsAll5Phase 1Brazil
58NCT02382874May 201514 December 2015Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical TrialFocal Segmental GlomerulosclerosisBiological: Intravenous injectionRoyan InstituteRecruiting2 Years14 YearsBoth5Phase 1Iran, Islamic Republic of
59EUCTR2014-002358-38-CZ28/04/201530 April 2019PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDYPROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDYFOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Aprovel (150 mg)
Product Name: Aprovel 150 mg Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Irbesartan
CAS Number: 138402-11-6
Other descriptive name: IRBESARTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Tablet
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Retrophin, Inc.Authorised Female: yes
Male: yes
100Phase 2Czech Republic;Belgium;Italy
60EUCTR2015-001039-18-Outside-EU/EEA4 August 2015Trial on the therapeutic effect of Tacrolimus in combination with low dosage corticosteroids compared with high dosage corticosteroids only, in patients with minimal change necrotic syndromeOpen-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) - T_OPTIMUM studyMinimal change nephrotic syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Prograf
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: TACROLIMUS
CAS Number: 104987-11-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Trade Name: Prograf
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: TACROLIMUS
CAS Number: 104987-11-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Trade Name: Solondo
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISOLONE
Other descriptive name: PREDNISOLONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Trade Name: Solondo
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISOLONE
Other descriptive name: PREDNISOLONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Astellas Pharma Korea, Inc.Not AvailableFemale: yes
Male: yes
152Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61ChiCTR-IPR-140053662014-09-0118 April 2017A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapyA prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapyAtypical membranous nephropathyLow-dose hormone plus cyclophosphamide (CTX) grou:hormone, cyclophosphamide, three months;hormone+CsA:hormone+CsA, three months;Department of Nephrology, China-Japan Friendship HospitalRecruiting1870BothLow-dose hormone plus cyclophosphamide (CTX) grou:20;hormone+CsA:20;Post-market
62ChiCTR-TRC-140050642014-09-0118 April 2017A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stageInvestigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosischronic kidney disease1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;Shanghai University of T.C.MRecruiting1860Both1:50;2:50;Pilot studyChina
63NCT02000440July 1, 201416 December 2017A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)Glomerulosclerosis, Focal SegmentalDrug: LosmapimodGlaxoSmithKlineNot recruiting18 Years70 YearsAll17Phase 2United States;Canada
64NCT02173106June 201419 February 2015A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous NephropathyOpportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical TrialIdiopathic Membranous Nephropathy;Proteinuria;Spontaneous Remission;Steroid Nephropathy;Cyclosporin OverdoseDrug: steroid & CyclosporinSun Yat-sen UniversityRecruiting14 Years75 YearsBoth180Phase 2China
65NCT02093533March 201429 January 2018Eculizumab in Primary MPGNEVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIAMembranoproliferative GlomerulonephritisDrug: EculizumabMario Negri Institute for Pharmacological ResearchAlexion Pharma Italy s.r.l.Not recruitingN/A75 YearsAll10Phase 2Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66EUCTR2013-003826-10-IT24/01/201419 February 2018ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITISEVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGNMembranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Soliris
Product Name: Soliris
Pharmaceutical Form: Concentrate for solution for injection/infusion
INN or Proposed INN: ECULIZUMAB
CAS Number: 219685-50-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
IRCCS- Mario Negri InstituteNot RecruitingFemale: yes
Male: yes
10Phase 2Italy
67NCT01955187January 201414 January 2019Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous NephropathyEuropean Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)MEMBRANOUS NEPHROPATHYDrug: TACROLIMUS;Drug: RITUXIMAB;Drug: METHYLPREDNISOLONE;Drug: CYCLOPHOSPHAMIDEHospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz;Hospital Universitario Fundación Alcorcón;Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre;Biobanco REDinREN;ERA-EDTA;REDinREN;Sociedad Española de Nefrología;Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;University Hospital, AachenNot recruiting18 YearsN/AAll86Phase 3Spain
68NCT01613118December 201311 June 2018Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisEfficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation StudyFocal Segmental GlomerulosclerosisDrug: RE-021 (Sparsentan);Drug: IrbesartanRetrophin, Inc.Not recruiting8 Years75 YearsAll100Phase 2United States;Belgium;Czechia;Italy;Czech Republic
69NCT01573533October 201319 November 2018A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSA Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte ß3 IntegrinPrimary Focal Segmental GlomerulosclerosisBiological: RituximabMayo ClinicUniversity Health Network, Toronto;National Institutes of Health (NIH);Genentech, Inc.;Rush University Medical Center;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting6 Years80 YearsAll20Phase 2United States;Canada
70ChiCTR-TRC-130037832013-07-0118 April 2017Compare the effects of intravenous to oral glucocorticoid therapies in MCNS patients with sever edemaCompare the effects of intravenous to oral glucocorticoid therapies in MCNS patients with sever edemaMinimal change nephroitic syndrometreatment group:intravenous methylprednisolon;control:oral prednisone ;the Affiliated Hospital of Guangdong Medical CollegeNot Recruiting1460Bothtreatment group:30;control:30;Phase 4 studyChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT01622738July 201319 February 2015A Study of RE-021 in Patients With Focal Segmental GlomerulosclerosisA Study of RE-021 in Patients With Focal Segmental GlomerulosclerosisPrimary Focal Segmental GlomerulosclerosisDrug: RE-021Retrophin, Inc.Not recruitingN/A50 YearsBoth0N/AUnited States
72NCT01762852April 201316 December 2017Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous NephropathyBEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous NephropathyGlomerulonephritis, MembranousDrug: Belimumab 10 mg;Drug: PlaceboGlaxoSmithKlineNot recruiting18 Years75 YearsAll0Phase 2United States;Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom
73EUCTR2011-000242-38-DE09/01/20134 November 2013A 2 year study to investigate belimumab in membranous nephropathyBEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathyIdiopathic Membranous Nephropathy (IMN)
MedDRA version: 16.0 Level: LLT Classification code 10027170 Term: Membranous nephropathy System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: BENLYSTA®
Product Name: BENLYSTA®
Product Code: GSK1550188 (Belimumab)
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: BELIMUMAB
CAS Number: 356547-88-1
Current Sponsor code: GSK1550881
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 80-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
GlaxoSmithKline Research & Development LtdNot RecruitingFemale: yes
Male: yes
94France;United States;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;Italy;United Kingdom
74NCT01791686January 201319 February 2015Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseA Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseDense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 GlomerulonephritisDrug: CDX-1135Celldex TherapeuticsNot recruiting4 YearsN/ABoth1Phase 1United States
75JPRN-UMIN0000089192012/09/152 April 2019The prospective multi-center study on the efficacy and safety of mizoribine for the treatment of aged nephrotic patients with primary membranous nephropathy.The patients with nephrotic syndrome due to primary membranous nephropathy.Treatment with a combination of mizoribine plus steroid therapy
Treatment with steroid monotherapy
The study group of treatment for aged patients with nephrotic syndrome.Not Recruiting65years-oldNot applicableMale and Female200Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT01665391August 201219 February 2015A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental GlomerulosclerosisPrimary Focal Segmental GlomerulosclerosisDrug: fresolimumab;Drug: PlaceboGenzyme, a Sanofi CompanyNot recruiting18 YearsN/ABoth36Phase 2United States;Brazil;Germany;Italy;Spain
77NCT01763580July 16, 201220 May 2019A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic SyndromeOpen-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS)MCNS;Minimal Change Nephrotic Syndrome (MCNS)Drug: Tacrolimus;Drug: PrednisoloneAstellas Pharma Korea, Inc.Not recruiting16 Years78 YearsAll144Phase 4Korea, Republic of
78EUCTR2011-006115-59-IT11/06/201231 July 2012A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) - GNM-2011MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp
MedDRA version: 14.1 Level: PT Classification code 10018372 Term: Glomerulonephritis membranous System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: MABTHERA*EV 1FL 50ML 500MG
Pharmaceutical Form: Solution for injection
CAS Number: 174722-31-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Trade Name: URBASON*IM EV 1F 250MG+1F 5ML
Pharmaceutical Form: Solution for infusion
CAS Number: 83-43-2
Concentration unit: g gram(s)
Concentration type: equal
Concentration number: 1-
Trade Name: MEDROL*10CPR DIV 4MG
Pharmaceutical Form: Tablet
CAS Number: 83-43-2
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: .4-
Trade Name: ENDOXAN BAXTER*50CPR RIV 50MG
Pharmaceutical Form: Coated tablet
CAS Number: 50-18-0
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: .2-
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIAAuthorisedFemale: yes
Male: yes
Italy
79EUCTR2012-000385-38-GB18/05/201231 March 2014A study to investigate belimumab in IMGNBEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous GlomerulonephropathyIdiopathic Membranous Glomerulonephropathy (IMGN)
MedDRA version: 16.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: BENLYSTA® (belimumab)
Product Name: Benlysta (belimumab)
Product Code: GSK1550188
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: Belimumab
CAS Number: 356547-88-1
Current Sponsor code: GSK1550188
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 80-
GlaxoSmithKline Research and Development LtdAuthorisedFemale: yes
Male: yes
18United Kingdom
80NCT01164098February 20121 October 2018Rituximab to Prevent Recurrence of ProteinuriaThe Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGSFSGS;ProteinuriaDrug: RituximabGeorge W. BurkeGenentech, Inc.;National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting7 Years65 YearsAll30Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81NCT01508468January 20125 September 2016Evaluate Rituximab Treatment for Idiopathic Membranous NephropathyProspective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)Idiopathic Membranous NephropathyDrug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)Assistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/ABoth80Phase 3France
82NCT03018535January 201227 May 2019Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous NephropathyA Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous NephropathyGlomerulonephritis, MembranousDrug: Rituximab;Drug: Methylprednisolone;Drug: CyclophosphamideAzienda Ospedaliera Spedali Civili di BresciaUniversity of Bari;Azienda Ospedaliera Brotzu;University of Messina;University of Milan;Universita di Verona;University of Chieti;University of Bologna;Azienda Sanitaria Locale Roma E;Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi;Regione Piemonte;University of Modena and Reggio Emilia;University of Pisa;University of Milano Bicocca;Humanitas Hospital, Italy;Azienda Ospedaliera Universitaria Policlinico;Fondazione Salvatore Maugeri;University of Bern;University of Alberta;Istituto Giannina GasliniNot recruiting18 YearsN/AAll76Phase 3Italy
83NCT01180036November 201121 January 2019MEmbranous Nephropathy Trial Of RituximabA Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)Idiopathic Membranous NephropathyDrug: Rituximab;Drug: CyclosporineMayo ClinicColumbia University;University of British Columbia;Ohio State University;Stanford University;University of Washington;University of Michigan;University of Alabama at Birmingham;Case Western Reserve University;The Cleveland Clinic;University of Kansas Medical Center;University of Manchester;University Health Network, Toronto;University of Toronto;CHU de Quebec-Universite Laval;Washington University School of Medicine;Florida International University;University of Mississippi Medical Center;New York University School of Medicine;Medical College of Wisconsin;University of Arizona;Sunnybrook Health Sciences Centre;Applied Health Research Centre;Fulk Family FoundationNot recruiting18 Years80 YearsAll126Phase 2/Phase 3United States;Canada
84NCT01845688November 201114 December 2015Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous NephropathyEfficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical StudyIdiopathic Membranous NephropathyDrug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo GranulewanglinNot recruiting18 Years70 YearsBoth72N/AChina
85NCT01451489October 13, 201116 December 2017The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental GlomerulosclerosisA Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental GlomerulosclerosisFSGSDrug: FK506;Drug: CyclophosphamideNanjing University School of MedicineNot recruiting14 Years65 YearsAll70N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86ChiCTR-TRC-110014542011-08-0118 April 2017Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trialTacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trialminimal change disease in adults;ICD10:N04.001Group A:Tacrolimus orally taken 0.5-1mg q12h for 36w, tape;Group B:prednisone orally taken for 36w, 1.0 mg/kg.d, tape;Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityNot RecruitingBothGroup A:60;Group B:60;Post-marketChina
87NCT01386554August 201111 June 2018Acthar for Treatment of Proteinuria in Membranous Nephropathy PatientsA Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)Proteinuria;Idiopathic Membranous NephropathyDrug: Repository Corticotropin Injection;Drug: PlaceboMallinckrodtNot recruiting18 YearsN/AAll60Phase 4United States;Canada;Chile;Mexico;Turkey
88JPRN-UMIN0000052312011/03/012 April 2019Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS)steroid dependent and frequently relapsing minimal change nephrotic syndromerituximab 375mg/m2 single-dose
1 time/6months
24 months follow up
Department of Medicine, Kidney Center, Tokyo Women's Medical UniversityNot Recruiting20years-old60years-oldMale and Female50Phase 3Japan
89NCT01282073March 201120 April 2015Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous NephropathyA Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous NephropathyGlomerulonephritis, MembranousDrug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin, low dose steroidKyungpook National UniversityHanmi Pharmaceutical Company LimitedRecruiting18 YearsN/ABoth62Phase 3Korea, Republic of
90NCT00977977December 23, 20107 October 2019Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRituximab Plus Cyclosporine in Idiopathic Membranous NephropathyNephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous GlomerulonephritisDrug: Rituximab Infusion;Drug: Oral CyclosporineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting18 YearsN/AAll30Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91NCT01799460December 201019 February 2015Study on Single-nucleotide-polymorphism in Idiopathic Membranous NephropathyMechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association StudiesIdiopathic Membranous NephropathyDrug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine;Drug: The immunosuppressive agentsShanghai University of Traditional Chinese MedicineRecruiting18 Years70 YearsBoth80N/AChina
92NCT01093781November 201019 February 2015Aliskiren in Patients With Idiopathic Membranous NephropathyA Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous NephropathyIdiopathic Membranous NephropathyDrug: AliskirenMayo ClinicNot recruiting18 Years80 YearsBoth0N/AUnited States
93ChiCTR-TRC-100008712010-09-0118 April 2017A randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndromeA randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndromeSteroid-sensitive primary nephrotic syndrome in childrenGroup A:Prednisolone (tablets) + Huai Qi Huang (particle);Group B:Prednisolone (tablets) + placebo (particle);Children's Hospital Affiliated to Fudan UniversityNanjing Children's HospitalNot Recruiting112BothGroup A:50;Group B:50;Post-marketChina
94NCT01185197September 201011 June 2018Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized StudyMyfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic SyndromeNephrosis, LipoidDrug: Myfortic plus low-dose steroid;Drug: PrednisoloneThe University of Hong KongNot recruiting18 Years65 YearsAll20Phase 4China
95NCT01162005July 20107 November 2016Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in ChildrenTherapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in ChildrenNephrotic SyndromeDrug: TacrolimusSeoul National University HospitalChong Kun Dang PharmaceuticalNot recruitingN/A18 YearsBoth80Phase 4Korea, Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96NCT01221181July 20104 March 2019Eculizumab Therapy for Dense Deposit Disease and C3 NephropathyEculizumab Therapy for Dense Deposit Disease and C3 NephropathyDense Deposit Disease;Membranoproliferative GlomerulonephritisDrug: EculizumabColumbia UniversityAlexion PharmaceuticalsNot recruiting18 YearsN/AAll6Phase 1United States
97NCT01161459June 201019 February 2015Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus SteroidResearch Institute of Nephrology, Jinling HospitalIdiopathic Membranous NephropathyDrug: Tripterygium wilfordii;Drug: FK506Zhi-Hong Liu, M.D.Not recruiting18 Years65 YearsBoth100N/AChina
98EUCTR2009-016003-26-GB06/05/201020 March 2012RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : MyforticRANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : MyforticPrimary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy
MedDRA version: 14.1 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders
Trade Name: Myfortic
Product Name: Myfortic 360mg Tablets
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: mycophenolic acid
CAS Number: 24280-93-1
Other descriptive name: mycophenolate sodium
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 360-
Trade Name: Myfortic
Product Name: Myfortic 180mg Tablets
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: mycophenolic sodium
CAS Number: 24280-93-1
Other descriptive name: mycophenolate sodium
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 180-
Product Name: Prednisolone
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisolone
CAS Number: 50-24-8
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 1.0-25.0
UHB NHS Foundation TrustAuthorisedFemale: yes
Male: yes
100United Kingdom
99NCT01093157February 201016 December 2017A Dose Escalation Study of Long-acting ACTH Gel in Membranous NephropathyA Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN)GlomerulonephritisDrug: Adrenocorticotrophic hormone ACTHUniversity Health Network, TorontoMallinckrodtNot recruiting18 Years72 YearsAll10Phase 1/Phase 2Canada
100ChiCTR-TQR-120026022009-10-0918 April 2017The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change NephropathyThe Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change NephropathyMinimal change nephrotic syndrome in childrenTreatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day;Treatment center of kidney disease, 281th hospital of PLANot Recruiting412BothTreatment:30;Control:30;Phase 1 studyChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101NCT01113385October 200919 October 2017Oral Galactose in Children With Steroid Resistant Nephrotic SyndromeEffect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot StudyFocal Segmental Glomerulosclerosis;Steroid Resistant Nephrotic SyndromeDrug: D-GalactoseChildren's Research InstituteNational Kidney FoundationNot recruiting2 Years21 YearsAll7N/AUnited States
102NCT01197040October 200916 December 2017Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic SyndromeLow Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic SyndromeNephrotic SyndromeDrug: Prednisone;Drug: acid mycophenolic (Myfortic)Assistance Publique - Hôpitaux de ParisNovartisNot recruiting18 YearsN/AAll117Phase 3France
103NCT00956059September 200919 February 2015Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisTherapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: prednisone, FK506, MMF;Drug: prednisoneXi’an Jiaotong University College of MedicineNot recruiting16 Years70 YearsBoth40N/AChina
104NCT01129557September 200919 October 2017Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseAldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney DiseaseProteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, MembranousDrug: Aliskiren;Drug: ValsartanColumbia UniversityNovartis PharmaceuticalsNot recruiting18 YearsN/AAll46Phase 4United States
105NCT01155141September 200919 October 2017Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTHIdiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTHKidney DiseasesDrug: H.P. Acthar GelStanford UniversityMallinckrodtNot recruiting16 Years65 YearsAll15Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106EUCTR2008-006750-17-IT14/04/200928 August 2012A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMOA prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMONephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS.
MedDRA version: 9.1 Level: LLT Classification code 10029171
MedDRA version: 9.1 Level: LLT Classification code 10058326
MedDRA version: 9.1 Level: LLT Classification code 10016832
Trade Name: MABTHERA
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Rituximab
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: MABTHERA
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Rituximab
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-
IST. DI RICERCHE FARMACOLOG. M. NEGRINot RecruitingFemale: yes
Male: yes
Italy
107ChiCTR-ONC-120028092009-01-0118 April 2017Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic SyndromeClinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic SyndromeIdiopathic nephrotic syndrome1:Given methylprednisolone according to the status of the patients ;The First Affiliated Hospital of Dalian Medical UniversityNot Recruiting1875Both1:90;OtherChina
108NCT00801463January 200919 February 2015Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisPrednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisProteinuria;Focal Segmental GlomerulosclerosisDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNot recruiting18 Years60 YearsBoth67N/AChina
109NCT00805753January 200919 February 2015Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous NephropathyA Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)Idiopathic Membranous NephropathyDrug: ACTHMayo ClinicQuestcor Pharmaceuticals, Inc.Not recruiting18 YearsN/ABoth20Phase 1United States;Canada
110NCT00814255December 200819 October 2017Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting1 Year65 YearsAll32Phase 2United States;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
111NCT00816478December 200821 September 2015Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability FactorEffect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisDrug: GalactoseNorth Shore Long Island Jewish Health SystemNot recruiting2 Years60 YearsBoth15Phase 1United States
112NCT00816504December 200814 September 2015Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5Focal Segmental GlomerulosclerosisDrug: GalactoseNorth Shore Long Island Jewish Health SystemMedical College of WisconsinNot recruiting2 Years60 YearsBoth0Phase 1United States
113NCT00694863July 200819 February 2015Treatment With Synthetic ACTH in High Risk Patients With Membranous NephropathyTreatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot StudyIdiopathic Membranous NephropathyDrug: tetracosactide hexacetaatRadboud UniversityDutch Kidney FoundationNot recruiting18 Years95 YearsBoth20Phase 2Netherlands
114EUCTR2007-005410-39-ES11/06/200819 March 2012“Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC“Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTACLa nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complejos inmunes a lo largo del espacio subepitelial, en ausencia de inflamación o cambios proliferativos en el resto del glomérulo. El origen exacto de este trastorno se desconoce sin embargo se sabe que la NMI es una causa frecuente de síndrome nefrótico (SN) del adulto.
MedDRA version: 9.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy
Trade Name: Advagraf 0,5mg
Pharmaceutical Form: Capsule*
INN or Proposed INN: tacrolimus
CAS Number: 104987-11-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,5-
Trade Name: Genoxal
Pharmaceutical Form: Tablet
INN or Proposed INN: ciclofosfamida
CAS Number: 50-18-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Trade Name: Dacortín 2,5mg
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisona
CAS Number: 53-03-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2,5-
Trade Name: Advagraf 1mg
Pharmaceutical Form: Capsule*
INN or Proposed INN: tacrolimus
CAS Number: 104987-11-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Trade Name: Advagraf 5mg
Pharmaceutical Form: Capsule*
INN or Proposed INN: tacrolimus
CAS Number: 104987-11-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Trade Name: Dacortín 5mg
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisona
CAS Number: 53-03-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Trade Name: Dacortín 30mg
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisona
CAS Number: 53-03-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.AuthorisedFemale: yes
Male: yes
40Spain
115EUCTR2008-001647-19-NL22/05/200819 March 2012Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeNTreatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeNMembranous nephropathy
MedDRA version: 9.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy
Trade Name: Synacthen Depot 1mg
Pharmaceutical Form: Suspension for injection
Radboud University Nijmegen Medical CenterAuthorisedFemale: yes
Male: yes
Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
116ChiCTR-TRC-080000982008-04-0118 April 2017Reseaech on integrated therapy of traditional Chinese medicine for membranous nephropathyReseaech on integrated therapy of traditional Chinese medicine for membranous nephropathyIdiopathic membranous nephropathyTreatment group:Integrated therapy of TCM;Control group:Prednisone and CTX;Longhua Hospital Affiliated to Shanghai University of TCMNot Recruiting1875BothTreatment group:95;Control group:95;Phase 1 studyChina
117NCT00782561April 200826 August 2019Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: FG-3019FibroGenNot recruiting12 Years64 YearsAll2Phase 1United States
118ChiCTR-TRC-100010242008-01-0118 April 2017Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosisTacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosisprimary focal segmental glomerulosclerosisgroup A:intravenous CTX 0.5-0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ;Shanghai Jiaotong University Affiliated Ruijin HospitalNot Recruiting1875Bothgroup A:30;group B:30;Post-marketChina
119NCT00550342January 200816 December 2017Rituximab Treatment of Focal Segmental GlomerulosclerosisAnti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)Drug: rituximabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Genentech, Inc.;Indiana UniversityNot recruiting5 Years60 YearsAll10Phase 2United States
120JPRN-UMIN0000009632007/10/012 April 2019Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndromeMinimal change nephrotic syndromeadministration of cyclosporineYoshihiko SaitoNot Recruiting20years-old75years-oldMale and Female30Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
121JPRN-UMIN0000010992007/10/012 April 2019Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndromeidiopathic membranous nephropathy associated with nephrotic syndromeSteroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.)
Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted.
Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine16years-oldNot applicableMale and Female50Phase 4Japan
122NCT00479622August 200719 February 2015Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus ErythematosusA Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: TRU-015Wyeth is now a wholly owned subsidiary of PfizerEmergent Product Development Seattle LLCNot recruiting18 Years70 YearsBoth20Phase 1United States
123NCT00464321May 200719 February 2015Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGSA Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisBiological: GC1008Genzyme, a Sanofi CompanyNot recruiting18 YearsN/ABoth16Phase 1United States;Germany;Italy;United Kingdom
124JPRN-UMIN0000006212007/03/012 April 2019Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remissionMinimal change nephrotic syndromePrednisolone (+), combination therapy (-)
Prednisolone (+), combination therapy (+)
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, JapanNot Recruiting16years-oldNot applicableMale and Female50Not selectedJapan
125NCT00405340October 20062 November 2015Rituximab in the Treatment of Idiopathic Membranous NephropathyRituximab in the Treatment of Idiopathic Membranous NephropathyMembranous NephropathyDrug: RituximabMayo ClinicGenentech, Inc.Not recruiting18 YearsN/ABoth20Phase 0United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
126NCT00354731August 200619 February 2015Efficacy of Pentoxifylline on Primary Nephrotic SyndromeClinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic SyndromeNephrotic SyndromeDrug: pentoxifylline;Drug: CorticosteroidNational Taiwan University HospitalNational Science Council, TaiwanNot recruiting20 Years80 YearsBoth62Phase 3Taiwan
127ChiCTR-OPN-170127892006-06-012 October 2017Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuriaGlucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuriafocal segmental glomerulosclerosisstudy group:prednisone treatment;control group:ACEI/ARB;Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineNot Recruiting1780Bothstudy group:52;control group:50;Post-marketChina
128EUCTR2005-004460-22-BE12/05/20067 October 2014Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis.Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis.focal and segmental glomerulosclerosisTrade Name: Neoral
Product Name: Neoral
Pharmaceutical Form: Capsule*
Trade Name: Medrol
Product Name: Medrol
Pharmaceutical Form: Tablet
Trade Name: zestril
Product Name: zestril
Pharmaceutical Form: Tablet
Hopital ErasmeAuthorisedFemale: yes
Male: yes
50Belgium
129EUCTR2005-004469-40-BE12/05/20067 October 2014Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathyMulticenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathyMembranous NephropathyTrade Name: Neoral
Product Name: Neoral
Pharmaceutical Form: Capsule*
Trade Name: zestril
Product Name: zestril
Pharmaceutical Form: Tablet
Hopital ErasmeAuthorisedFemale: yes
Male: yes
50Belgium
130JPRN-C0000001582006/03/012 April 2019Mizoribin for primary nephrotic syndrome in children(JSRDC09)Steroid-sensitive nephrotic syndromemizoribine+prednisoloneJapanese Study Group of Renal Disease in Children(JSRDC)Not Recruiting1years-old10years-oldMale and Female50Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
131NCT00302523March 200619 February 2015Tacrolimus Treatment of Patients With Idiopathic Membranous NephropathyTacrolimus Treatment of Patients With IdiopathicIdiopathic Membranous NephropathyDrug: TacrolimusNanjing University School of MedicineNot recruiting18 Years60 YearsBoth16N/AChina
132NCT00302536March 200619 February 2015Tacrolimus Treatment of Patients With Idiopathic Focal Segmental GlomerulosclerosisTacrolimus Treatment of Patients With Idiopathic Focal SegmentalFocal GlomerulosclerosisDrug: TacrolimusNanjing University School of MedicineNot recruiting15 Years50 YearsBoth0N/AChina
133NCT00983034March 200619 February 2015The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous NephropathyProspective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous NephropathyNephrotic Syndrome;Glomerulonephritis;Membranous NephropathyDrug: lansoprazole, amoxicillin, clarithromycinIstanbul UniversityNot recruiting18 Years70 YearsBoth70N/ATurkey
134NCT00275613November 200519 February 2015Pilot Study of Rituximab for Membranoproliferative GlomerulonephritisPilot Study of Rituximab for Membranoproliferative GlomerulonephritisGlomerulonephritis, MembranoproliferativeDrug: RituximabMayo ClinicNot recruiting18 YearsN/ABoth10Phase 1United States
135NCT00193648July 200519 February 2015Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)Novel Therapies for Resistant FSGSFocal GlomerulosclerosisDrug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira)North Shore Long Island Jewish Health SystemUniversity of North Carolina;The Cleveland ClinicNot recruiting2 Years40 YearsBoth21Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
136JPRN-UMIN0000046532005/01/012 April 2019The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNSminimal change nephrotic syndromecyclosporine A 2-3mg/kg/dayYokohama city university graduate school of medicineNot Recruiting16years-oldNot applicableMale and Female20Not applicableJapan
137NCT00135811November 200419 February 2015Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)Focal Segmental Glomerulosclerosis Clinical TrialGlomerulosclerosis, FocalDrug: Cyclosporin;Drug: MMF and DexamethasoneNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)The Cleveland ClinicNot recruiting2 Years40 YearsBoth207Phase 3United States
138NCT00362531November 200419 February 2015Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic SyndromePhase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic SyndromeIdiopathic Membranous Nephropathy;Nephrotic SyndromeDrug: tacrolimus combined with prednisonePeking UniversityNot recruiting18 Years70 YearsBothPhase 2/Phase 3
139NCT00425217August 200419 February 2015Rituximab in Membranous NephropathyThe Use of Rituximab in the Treatment of Idiopathic Membranous NephropathyMembranous NephropathyDrug: RituximabMayo ClinicGenentech, Inc.Not recruiting18 YearsN/ABoth15Phase 2/Phase 3United States
140ChiCTR19000225182004-04-0123 April 2019Clinical trial for corticosteroids monotherapy in the treatment of seronegative hepatitis B virus-associated membranous nephropathy.Efficacy and safety of corticosteroids in 26 cases of seronegative hepatitis B virus-associated membranous nephropathySeronegative Hepatitis B Virus-associated Membranous NephropathyCase series:give corticosteroids(Methylprednisolone);Tianjin HospitalNot RecruitingBothCase series:26;Phase 0China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
141JPRN-C0000003682004/04/012 April 2019Multicenter study for combined therapy of prednisolone and mizoribine in idiopathic membranous nephropathy with refractory nephrotic syndromemembranous nephropathy with primary steroid resistant nephrotic syndromemizoribine once a day per os administration (150mg) after breakfast for 2years.



mizoribine 3 times a day per os administration (50mg each) after meals for 2years.
Project team for treatment of refractory nephrotic syndromeThe Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, JapanNot Recruiting16years-old75years-oldMale and Female100Not selectedJapan
142ChiCTR-TRC-090005392004-03-0118 April 2017Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapyClinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapyNephrotic DiseaseS:Patients receive tacrolimus combined with prednison for six months;L:Patients receive tacrolimus combined with prednison for 24 months;Second Hospital of Jilin UniversityNot Recruiting1669BothS:10;L:10;Pilot studyChina
143NCT00404833January 200319 February 2015Mycophenolate Mofetil in Membranous Nephropathy and Focal SegmentalA Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)Glomerulonephritis, Membranous;Glomerulosclerosis, FocalDrug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucilHospital Authority, Hong KongThe University of Hong KongNot recruiting18 Years65 YearsBoth16Phase 3China
144NCT00050713December 17, 200216 December 2017Sirolimus Therapy for Idiopathic and Lupus Membranous NephropathySirolimus Therapy in Idiopathic and Lupus Membranous NephropathyMembranous Glomerulonephritis;Lupus Membranous NepropathyDrug: SirolimusNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting13 YearsN/AAll12Phase 2United States
145NCT00040508June 200219 February 2015Sirolimus for Focal Segmental GlomerulosclerosisSirolimus for Focal Segmental GlomerulosclerosisFocal GlomerulosclerosisDrug: SirolimusNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruitingN/AN/ABoth30Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
146NCT00135967May 200219 February 2015Mycophenolate Mofetil in Membranous NephropathyTreatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot StudyGlomerulonephritis, MembranousDrug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9Radboud UniversityHoffmann-La RocheNot recruiting18 Years75 YearsBoth30Phase 2/Phase 3Netherlands
147JPRN-C0000000092001/04/012 April 2019Treatment for steroid-resistant nephrotic syndrome in children: a combination of cyclosporine and prednisolone in minimal change and a combination of methylprednisolone, cyclosporine and prednisolone in FSGSSteroid-resistant nephrotic syndrome in childrenCyclosporine+prednisolone
Methylprednisolone+cyclosporine+prednisolone
Japanese Study Group of Renal Disease in ChildrenNot Recruiting1years-old18years-oldMale and Female60Not selectedJapan
148JPRN-C0000003792001/04/012 April 2019Prednisolone only and a combination of prednisolone and mizoribine for primary nephrotic syndrome relapsed within six mounths after first onset in children: A randomized controlled trial of efficacy and safety (JSRDC06)Steroid-sensitive nephrotic syndromeprednisolone
mizoribine+prednisolone
Japanese Study Group of Renal Disease in Children(JSRDC)Not Recruiting1years-old10years-oldMale and Female50Not selectedJapan
149NCT00007475December 200019 October 2017Permeability Factor in Focal Segmental GlomerulosclerosisPermeability Factor in Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisProcedure: Plasma exchange;Drug: CyclophosphamideNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruitingN/AN/AAll15Phase 1/Phase 2United States
150NCT00004990March 200019 February 2015Once-A-Month Steroid Treatment for Patients With Focal Segmental GlomerulosclerosisPulse Dexamethasone in Focal Segmental GlomerulosclerosisGlomerulonephritis;Nephrotic SyndromeDrug: DexamethasoneNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruitingN/AN/ABoth20Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
151NCT00001959December 199919 October 2017Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II StudyFibrosis;Focal Glomerulosclerosis;Kidney Failure;Nephrotic Syndrome;ProteinuriaDrug: PirfenidoneNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 YearsN/AAll21Phase 2United States
152NCT00135954July 199719 February 2015Treatment of Patients With Idiopathic Membranous NephropathyTreatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive TherapyGlomerulonephritis, MembranousDrug: Cyclophosphamide and steroidsRadboud UniversityNot recruiting18 Years75 YearsBoth29Phase 3Netherlands

先頭へ